• Vaccine Name: rMCMV-TRP2
• Target Pathogen: Cancer
• Target Disease: Cancer
• Vaccine Ontology ID: VO_0004716
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• Trp2 gene engineering:
  • Type: Recombinant vector construction
  • Description: An unmodified melanoma antigen, mouse tyrosinase-related protein 2 (TRP2), in mouse cytomegalovirus (MCMV) (Xu et al., 2013).
  • Detailed Gene Information: Click Here.
• Vector:
  • Vector name:
  • VO vector ID: VO_0001073
• Preparation: An unmodified melanoma antigen, mouse tyrosinase-related protein 2 (TRP2), in mouse cytomegalovirus (MCMV)(Xu et al., 2013).
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Vaccination Protocol: Prophylactic vaccination of the mice with a single dose of MCMV-TRP2 (Xu et al., 2013).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: Mice were subcutaneously (s.c.) challenged with 2 × 10^5 B16/F10 cells in 100 μl PBS in the shaved right flank (Xu et al., 2013).
• Efficacy: Therapeutic vaccination with MCMV-TRP2 prolonged the survival of the mice challenged with B16 cells. Furthermore, vaccination with MCMV-TRP2 five months before tumor challenge still induced tumor rejection, which indicated that the vaccine induced long-term protection (Xu et al., 2013).